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SUMMARY – A 64-year-old female receiving clopidogrel and aspirin antiaggregation therapy 
after percutaneous coronary intervention for non-STEMI myocardial infarction developed nontrau-
matic bilateral subdural hematoma with dizziness, vertigo and headache. Craniotomy had to be po-
stponed because of reduced ADP platelet aggregability. Four days after clopidogrel withdrawal and 
transfusion of 12 platelet concentrate units, ADP aggregation transiently normalized and bilateral 
trepanation with hematoma evacuation was performed. Th e procedure was followed by excellent 
neurologic and clinical recovery; however, decreased platelet aggregability was recorded by postope-
rative day 12 despite strict clopidogrel and other platelet inhibitor withdrawal. Suspicion of Glanz-
mann thrombastenia was excluded by fl ow cytometry. Two weeks after neurosurgery, the right fe-
moral vein thrombosis was detected by color doppler ultrasonography and therapy with fractionated 
heparin was initiated, followed by warfarin. Th e risk and incidence of hemorrhagic complications of 
antiaggregation and anticoagulation therapy are discussed. Caution is warranted on prescribing this 
potentially harmful therapy to older patients, generally burdened with other chronic comorbidities.  
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Introduction 
Nontraumatic chronic subdural hematoma is a fre-
quent clinical entity in daily neurosurgical routine. It 
usually occurs in elderly people with a peak incidence 
in the eighth decade of life1. Studies have identifi ed 
age, sex, falls, and anticoagulant or antithrombotic 
therapy as the major risk factors for the development 
of chronic subdural hematoma. Th e higher incidence 
of chronic subdural hematoma in those older than 65 
is associated with fragility of the bridging cerebral 
veins due to brain atrophy, a higher tendency to falls, 
and more common use of anticoagulant (warfarin) 
and antithrombotic (aspirin and clopidogrel) therapy. 
In addition, brain movements facilitate arachnoid 
membrane tearing even with trivial trauma. Th e male 
predominance is also associated with greater exposure 
to injuries. Previous trauma in combination with anti-
coagulant or antithrombotic therapy may also increase 
the risk of chronic subdural hematoma. Review ar-
ticles report on a varying proportion of patients with 
chronic subdural hematoma, describing it as a condi-
tion accompanying arterial aneurysm rupture, lumbar 
puncture, anticoagulant therapy, acquired coagulopa-
thy and thrombocytopenia1-5.    
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Case Report
A 64-year-old female patient was admitted for 
weakness, mental confusion, orthostatic instability, 
and urinary incontinence. Th e patient denied previ-
ous injuries and bleeding episodes. Her mother died 
from cerebrovascular thrombosis and her father from 
myocardial infarction. Her personal medical history 
included long-term hypertension, type 2 diabetes, 
and hyperlipoproteinemia. Two years before, she had 
undergone percutaneous angioplasty for anterolateral 
(non-STEMI) myocardial infarction, upon which 
ischemic pain resolved and she was discharged from the 
hospital on dual antiaggregation therapy with aspirin 
and clopidogrel. In two months, however, the patient 
experienced recurrent episodes of ischemic chest pain; 
repeat coronarography revealed 60%-70% stenosis of a 
distal segment of the left coronary artery, 70% steno-
sis of the left anterior descending artery (LAD), and 
90% stenosis of the proximal D1 segment, which was 
managed by endoprosthesis placement. In addition, 
there was subocclusion of a proximal segment of the 
hypoplastic circumfl exed coronary artery, which had 
formed collaterals to the right coronary artery. Dual 
antiaggregation therapy (aspirin and clopidogrel) was 
continued and unfortunately complicated by bleeding 
duodenal ulcer four months later. After short therapy 
discontinuation, clopidogrel therapy was reintroduced 
because coronary disease was considered to pose 
greater risk than gastroduodenal bleeding.
Ten months later, the patient presented with bi-
lateral subdural hematoma (Fig. 1). Neurosurgical 
treatment was indicated but evacuation of the hema-
toma had to be postponed due to reduced (13%) ADP 
pathway platelet aggregation. Other biochemical pa-
rameters were normal (Table 1). Four days of clopi-
dogrel withdrawal and platelet transfusion, the ADP-
induced platelet aggregation normalized (78%) (Table 
Fig. 1. Computed tomography image of bilateral subdural 
hematoma.
Table 1. Blood parameters at admission
Parameter                                                                                Measured value            Unit              Reference value
Platelet aggregation response to ADP 
Platelet aggregation response to epinephrine
Platelet aggregation response to collagen
Red blood cells (female)
Hemoglobin (female)







































ADP = adenosine diphosphate
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2). Bilateral trepanation and hematoma evacuation 
were performed and resulted in excellent neurologic 
recovery. Th e patient was discharged from the hospi-
tal; however, on postoperative day 14 she was readmit-
ted for the left iliofemoral vein thrombosis diagnosed 
by doppler ultrasound. Th e previous hypocoagulation 
condition caused by antiaggregation therapy had now 
turned to a thrombophilic (hypercoagulation) condi-
tion due to recent brain surgery (thromboplastin re-
lease), bed rest (retarded venous fl ow), and urinary 
infection (infl ammatory cytokines, fi brinogen). Th e 
patient was administered heparin, followed by war-
farin in a slightly reduced dosage because of bleed-
ing episodes in her recent medical history, with good 
clinical response. Aggregation tests were repeated to 
show reduced platelet aggregability in spite of taking 
no antiaggregation therapy (Table 3). Th is fi nding 
raised suspicion of underlying yet undiagnosed Glan-
zmann thrombasthenia; however, fl ow cytometry was 
negative for CD42 (GPIIb) and CD61(GPIIIb) (Ta-
ble 1). 
Discussion
Th e majority of patients with chronic subdural 
hematoma are men older than 65, with a history of 
head trauma, or taking anticoagulant and/or anti-
aggregation therapy. Older age is associated with a 
higher likelihood of brain atrophy and bridging vein 
fragility, the risk of falls and frequent use of antico-
agulant and antiaggregation therapy. Th e incidence of 
chronic subdural hematoma has been estimated to 5.3 
per 100,000 surgically treated individuals. Previous 
head trauma is reported in 60%-80% of cases; howev-
er, mild traumatic events may proceed unrecognized, 
leading to an increased proportion of allegedly ‘spon-
taneous’ cases of chronic subdural hematoma6. 
Diagnostic procedure for chronic subdural hema-
toma has been well established and includes neuroim-
aging techniques of multi-slice computed tomography 
(MSCT) and magnetic resonance imaging (MRI)2,7. 
Density of blood coagulum varies with the age of he-
matoma; therefore, after three weeks, a chronic hema-
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Table 3. Blood tests on day 15 of trephination
Parameter
Platelet aggregation response to ADP 
Platelet aggregation response to epinephrine
Platelet aggregation response to collagen
Prothrombin time
Fibrinogen
Activated partial thromboplastin time
PFA 100 collagen/epinephrine
von Willebrand's factor 





















ADP= adenosine diphosphate; PFA = Dade Behring PFA-100 platelet function analyzer; it  also measures ex vivo platelet binding to collagen/
epinephrine (CEPI) or collagen/adenosine diphosphate (CADP)
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toma visualized by an imaging technique will appear 
as a hypodense area. Th e most common symptoms 
of chronic subdural hematoma are gait disturbance, 
hemiparesis, headache, dementia, urinary inconti-
nence and consciousness disturbance1. Our patient 
developed urinary incontinence, mental confusion, 
headache and gait disturbance. Her risk factors for 
chronic subdural hematoma included repeat episodes 
of gastroduodenal bleeding, long-standing antiag-
gregation therapy and infection. Bilateral hematomas 
and recurrent platelet aggregation reduction also sug-
gested the possible development of thrombasthenia. 
In general, acquired or hereditary pathologic 
bleeding can result from defects in the procoagulant 
mechanisms, defects in the mechanisms of hemosta-
sis control, and abnormal fi brinolysis. Defects in pro-
coagulant mechanisms may include platelet count or 
function abnormalities, coagulation factor defects, or 
vascular defects. Platelet function disorders include 
defects of platelet adhesion, aggregation and activa-
tion, secretion defects, signaling pathway defects, and 
defects in platelet size or membrane phospholipids. 
Th ese may be inherited, or more commonly, acquired. 
Inherited defects are von Willebrand’s disease and 
Bernard-Soulier syndrome (adhesion), Glanzmann 
thrombasthenia (aggregation) and Chédiak-Higashi 
syndrome (secretion defect). Our patient had normal 
platelet count and no signs of cardiovascular disease, 
therefore repeat tests occasionally indicating reduced 
platelet aggregability raised suspicion of Glanzmann 
thrombasthenia. Glanzmann thrombasthenia is an 
autosomal recessive syndrome with the incidence of 
1 per million, and implies qualitative and quantitative 
abnormalities of the GpIIb/GpIIIa platelet membrane 
glycoprotein complex8-12.
Acquired dysfunction is most commonly associ-
ated with antiaggregation agents that are currently 
widely and frequently unselectively used. Th ere are 
many other drugs demonstrated to infl uence platelet 
Fig. 2. Ultrasonographic image of venous thrombosis.
Komentar: TROMBOZIRANA VFC S Komentar: TROMBOZIRANA VSM S
Komentar: TROMBOZIRANA VFC S
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function, e.g., non-steroidal anti-infl ammatory drugs 
(NSAIDs), thienopyridines, GPIIb/IIIa receptor an-
tagonists, drugs that increase platelet cAMP, antico-
agulant and fi brinolytic agents, cardiovascular drugs 
(nitrates, furosemide, angiotensin-converting enzyme 
inhibitors (ACEI), calcium channel blockers), cyto-
statics (danorubicin, mitomycin), psychiatric drugs 
(chlorpromazine, haloperidol) and antihistamines. 
Dual antiplatelet therapy with aspirin (acetylsalicylic 
acid, ASA) and thienopyridine (clopidogrel) is stan-
dard care after coronary stenting. Besides the use of 
ASA and clopidogrel, the use of nitrates, furosemide, 
ACEI and calcium channel blockers was also estab-
lished by history data.   
In a retrospective study of 123 patients with spon-
taneous subdural hematoma, 76% of patients were 
found to take aspirin (n=78) and warfarin (n=15), sug-
gesting the use of aspirin to increase signifi cantly the 
risk of cerebral hemorrhage and associated complica-
tions13. Clinical evidence for the effi  cacy of clopidogrel 
bisulfate relies on two double-blind studies, CURE 
and CAPRIE. Th e CURE study demonstrated the 
risk of myocardial infarction and stroke to be reduced, 
while the rate of gastrointestinal hemorrhage was 
1.3%, of intracranial hemorrhage 0.1% and of fatal 
hemorrhage 0.2%14-16.
Th e eff ect of ASA and clopidogrel on platelets lasts 
throughout the platelet life span, for about 7 days; 
therefore, in our patient platelet aggregation tests 
yielded abnormal results on admission. Later on, ag-
gregation tests normalized due to transfused platelets 
and platelets formed de novo in the body. Th e addition 
of transfused platelets, post-hemorrhage reactive hy-
percoagulation, operative procedures (hyperfi brino-
genemia, tissue thromboplastin release) and bed rest 
with venous stasis probably favored the development 
of iliac vein thrombosis on day 14 of craniotomy.
Th e complications of hemorrhage and chronic sub-
dural hematoma call for due caution on the selection 
and follow up of patients prescribed antiaggregation 
agents. Th is in particular applies to elderly patients, 
where the risk of bleeding is already increased due to 
fragile capillaries, and in a very small but signifi cant 
group of patients with inborn platelet function dis-
order. However, due to limited resources, testing for 
platelet aggregation cannot be routinely done prior to 
introducing antiaggregation therapy. Th erefore, due 
attention should be paid to patients with a history of 
mucocutaneous bleeding, thrombosis or skin necrosis. 
Some new drugs like direct thrombin and Factor X 
inhibitors (dabigatran and rivaroxaban) have already 
passed phase III clinical trials on prophylaxis and pre-
vention of venous thrombosis. Th ese agents may com-
pletely replace warfarin and vitamin K antagonists in 
the treatment and prevention of venous thromboem-
bolism because they require no activity monitoring or 
dose adjustment. For now, studies of their potential 
eff ects in the prevention of arterial thromboembolism 
are yet to be expected. Th us, due caution is still war-
ranted on selecting patients prescribed antiaggrega-
tion agents,  and their side eff ects should be strictly 
monitored.
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Sažetak
NETRAUMATSKI OBOSTRANI SUBDURALNI HEMATOM UZROKOVAN ANTIAGREGACIJSKOM 
TERAPIJOM: PRIKAZ SLUČAJA I PREGLED LITERATURE
A. Vuk, V. Stančić, G. Rinčić, M. Ledinsky, Lj. Grbac i N. Stančić
U 64-godišnje bolesnice koja je zbog ne-STEMI srčanog infarkta dobivala aspirin i klopidogrel razvio se netraumatski 
obostrani subduralni hematom praćen smušenošću, vrtoglavicom i glavoboljom. Kod prijma je utvrđena smanjena agrega-
cija trombocita u ADP testu pa je kraniotomija i dekompresija odgođena za 4 dana. Četiri dana nakon prestanka uzimanja 
klopidogrela i aspirina te uz transfuziju od 12 doza trombocita prolazno se normalizirala agregabilnost trombocita pa je 
učinjena obostrana trepanacija i uklonjeni su hematomi. Slijedio je odličan neurološki oporavak. Smanjena agregabilnost 
trombocita bila je prisutna do 12. poslijeoperacijskog dana. Sumnja na Glanzmannovu trombasteniju isključena je pro-
točnom citometrijom. Četrnaestoga poslijeoperacijskog dana nastala je tromboza desne femoralne vene koja je liječena 
smanjenim dozama heparina i varfarina. Uz prikaz bolesnice analizira se rizik od krvarenja i tromboze u bolesnika koji 
uzimaju antitrombocitne lijekove. Preporuča se oprez u starijih bolesnika kod kojih su prisutne i druge teške bolesti, što 
povećava rizik od krvarenja. 
Ključne riječi: Ključne riječi: Hematom, subduralni – dijagnostika; Hematom, subduralni – etiologija; Hematom, subduralni 
– terapija; Antikoagulansi – terapijska primjena; Progresija bolesti; Starija osoba; Prikaz slučaja
